• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[拟钙剂、作用机制及治疗应用]

[Calcimimetics, mechanisms of action and therapeutic applications].

作者信息

Ureña P, Legoupil N, de Vernejoul M C

机构信息

Service de néphrologie-dialyse, Clinique de l'Orangerie, Aubervilliers (93).

出版信息

Presse Med. 2005 Sep 10;34(15):1095-100. doi: 10.1016/s0755-4982(05)84125-9.

DOI:10.1016/s0755-4982(05)84125-9
PMID:16334889
Abstract

The extracellular calcium-sensing receptor (CaR) on the parathyroid cell surface negatively regulates secretion of parathyroid hormone (PTH). Its activation by small changes in the extracellular concentration of ionized calcium (ec[Ca2+]) decreases PTH secretion and secondarily bone turnover. CaR is an ideal target for compounds that may be developed to modulate its activity - activating calcimimetics and inhibiting calcilytics. Calcimimetics can amplify the sensitivity of the CaR to ec(Ca2+), thereby suppressing PTH levels and in turn reducing blood Ca++. They dose-dependently reduce the secretion of PTH in cultured parathyroid cells, in animal models and in humans. In uremic animals, these compounds prevent parathyroid cell hyperplasia when given at the onset of the disease and stop cell proliferation if they are administered afterwards, when the hyperplasia already exists. They normalize plasma PTH levels and bone remodeling. In uremic patients undergoing hemodialysis, calcimimetics reduce plasma PTH concentrations in the short (12 weeks) and long (2 years) terms. They also reduce serum levels of calcium-phosphorus product. Calcimimetics are therefore an alternative for the treatment of secondary hyperparathyroidism, particularly in dialysis patients, when increased serum levels of calcium-phosphorus product, the attendant risk of cardiovascular calcification, and its lack of efficacy limit use of the standard treatment.

摘要

甲状旁腺细胞表面的细胞外钙敏感受体(CaR)对甲状旁腺激素(PTH)的分泌起负调节作用。细胞外游离钙(ec[Ca2+])浓度的微小变化激活该受体后,会减少PTH分泌,进而降低骨转换。CaR是可能开发的用于调节其活性的化合物的理想靶点——激活剂为拟钙剂,抑制剂为拟钙解剂。拟钙剂可增强CaR对ec(Ca2+)的敏感性,从而抑制PTH水平,进而降低血钙浓度。它们在培养的甲状旁腺细胞、动物模型和人体中呈剂量依赖性地减少PTH分泌。在尿毒症动物中,这些化合物在疾病发作时给药可预防甲状旁腺细胞增生,在增生已经存在时给药则可阻止细胞增殖。它们可使血浆PTH水平和骨重塑恢复正常。在接受血液透析的尿毒症患者中,拟钙剂在短期(12周)和长期(2年)内均可降低血浆PTH浓度。它们还可降低血清钙磷乘积水平。因此,当血清钙磷乘积水平升高、随之而来的心血管钙化风险以及标准治疗缺乏疗效限制了其使用时,拟钙剂是治疗继发性甲状旁腺功能亢进的一种替代方法,尤其适用于透析患者。

相似文献

1
[Calcimimetics, mechanisms of action and therapeutic applications].[拟钙剂、作用机制及治疗应用]
Presse Med. 2005 Sep 10;34(15):1095-100. doi: 10.1016/s0755-4982(05)84125-9.
2
Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.拟钙剂的药理及临床特性:钙受体激活剂为控制甲状旁腺功能亢进提供了一种创新方法。
Pharmacol Ther. 2006 Mar;109(3):339-65. doi: 10.1016/j.pharmthera.2005.06.019. Epub 2005 Aug 15.
3
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.参与细胞内钙(Ca2+)调节的功能蛋白在药物研发中的应用:细胞外钙受体及通过拟钙剂控制继发性甲状旁腺功能亢进的创新医学方法。
J Pharmacol Sci. 2005 Mar;97(3):355-60. doi: 10.1254/jphs.fmj04007x6. Epub 2005 Mar 17.
4
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.盐酸西那卡塞:一种治疗慢性肾脏病所致继发性甲状旁腺功能亢进的新疗法。
J Ren Nutr. 2006 Jul;16(3):253-8. doi: 10.1053/j.jrn.2006.04.010.
5
[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].西那卡塞——一种用于治疗尿毒症、甲状旁腺癌或原发性甲状旁腺功能亢进患者继发性甲状旁腺功能亢进的新药
Ugeskr Laeger. 2006 Jan 3;168(1):29-32.
6
[Clinical use of calcimimetics in the treatment of hyperparathyroidisms].拟钙剂在甲状旁腺功能亢进症治疗中的临床应用
Med Sci (Paris). 2004 Nov;20(11):973-8. doi: 10.1051/medsci/20042011973.
7
Cinacalcet in hyperfunctioning parathyroid diseases.西那卡塞在甲状旁腺功能亢进疾病中的应用
Ther Apher Dial. 2009 Oct;13 Suppl 1:S7-S11. doi: 10.1111/j.1744-9987.2009.00768.x.
8
Calcimimetic agents: review and perspectives.
Kidney Int Suppl. 2003 Jun(85):S91-6. doi: 10.1046/j.1523-1755.63.s85.22.x.
9
[Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].[通过钙受体控制抑制甲状旁腺激素(PTH)分泌的药物(拟钙剂)——对钙调节的PTH分泌设定点的影响]
Clin Calcium. 2005 Jan;15(1):71-8.
10
[Calcimimetics--a new treatment for hyperparathyroidism?].拟钙剂——甲状旁腺功能亢进症的一种新疗法?
Pol Merkur Lekarski. 2005 May;18(107):581-4.